← Product Code [JLW](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JLW) · K960195 # THYROCHEK ONE-STEP RAPID TSH ASSAY (K960195) _Franklin Diagnostics, Inc. · JLW · Apr 15, 1996 · Clinical Chemistry · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JLW/K960195 ## Device Facts - **Applicant:** Franklin Diagnostics, Inc. - **Product Code:** [JLW](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JLW.md) - **Decision Date:** Apr 15, 1996 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 862.1690 - **Device Class:** Class 2 - **Review Panel:** Clinical Chemistry ## Indications for Use This new immunometric assay device is a single-use Class II medical device for professional use that is designed to indicate whether a serum sample contains TSH in a concentration > 5 µIU/ml. ## Device Story ThyroChek is a single-use immunometric assay for professional use; detects TSH concentrations > 5 µIU/ml in serum samples. Device provides qualitative indication of TSH levels; assists clinicians in thyroid function assessment. Operation involves testing serum samples; results compared against predicate device performance. Benefits include rapid identification of elevated TSH levels in clinical settings. ## Clinical Evidence Bench testing and comparative study performed. Parallel testing of 328 patient samples against predicate device: 65/66 samples with TSH > 5 µIU/ml correctly identified; 262/262 samples with TSH < 5 µIU/ml correctly identified. Intra-assay coefficient of variation < 3%. Cross-reactivity studies showed no interference from hCG (up to 150,000 mIU/ml), LH, or FSH (> 40 mIU/ml). Interference testing confirmed no impact from glucose, uremic metabolites, lipids, or hemolyzed red blood cells. ## Technological Characteristics Immunometric assay; single-use; professional use. Designed for serum sample analysis. No specific materials, connectivity, or software algorithms described. ## Regulatory Identification A thyroid stimulating hormone test system is a device intended to measure thyroid stimulating hormone, also known as thyrotrophin and thyrotrophic hormone, in serum and plasma. Measurements of thyroid stimulating hormone produced by the anterior pituitary are used in the diagnosis of thyroid or pituitary disorders. ## Predicate Devices - Immunolite Third Generation TSH Assay ([K930007](/device/K930007.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} J. Ehrenkranz, M.D. p.3 K960195 # 14. SMDA Summary This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. This new immunometric assay device is a single-use Class II medical device for professional use that is designed to indicate whether a serum sample contains TSH in a concentration > 5 µIU/ml. The intended use, technical characteristics, efficacy, and safety of this new device are substantially equivalent at detecting TSH > 5 µIU/ml to a number of other TSH immunoassays that have been commercially available both before and after 1978, and Franklin believes that demonstration of substantial equivalence to a legally marketed predicate device in accordance with section 510(k) has been demonstrated. This document contains the results of a number of validation studies which compares the performance of ThyroChek at detecting TSH > > 5 µIU/ml to that of a predicate medical device, Immunolite Third Generation TSH Assay, 510(k) number K930007. The validating studies performed and the results obtained are as follows: 1. Quantitative Recovery. This demonstrated the ability of this assay to discriminate serum samples containing TSH at concentrations of 5.2, 5.7, and 6.5 µIU/ml, as determined by the predicated device, from samples containing TSH at a concentration of 4.1 and 4.5 µIU/ml. 2. Serial Dilution. This demonstrated the ability of this assay to distinguish serum samples containing TSH > 5 µIU/ml from those with a TSH concentration diluted below 5 µIU/ml. 3. Coefficient of Variation. 5 sets of 30 replicates showed uniform results, that is 30 identical results, using ThyroChek in 4 of 5 sets and 29 of 30 replicates agreed in 1 of 5 sets. Additionally 25 samples measured in duplicate showed 100% agreement between both replicates. This represents an intra-assay coefficient of variation of less than 3%. 4. Parallelism. 328 patient samples were assayed in parallel by the predicate device and by ThyroChek. 65 of 66 patients with TSH > 5 µIU/ml, as determined by the predicate device, were correctly identified using ThyroChek. 262 of 262 patients with TSH < 5 µIU/ml, as determined by the predicate device, were correctly identified by ThyroChek. 5. Cross-Reactivity. Because of the structural similarity between TSH and hCG, LH, and FSH, studies were performed to determine if maximal clinical concentrations of these hormones would interfere with ThyroChek performance. These studies showed that hCG, in concentrations as high as 150,000 mIU/ml, and LH / FSH > 40 mIU/ml, as encountered in 17 postmenopausal women, did not produce false negative or positive test results or affect ThyroChek's ability to determine whether a serum sample contained > 5 µIU/ml. {1} J. Ehrenkranz, M.D. p.4 6. Interference. Elevated concentrations of glucose, uremic metabolites, lipids, or hemolyzed red blood cells as encountered in patient samples did not interfere with device performance. This 510(k) Summary Statement was revised by J. Ehrenkranz, M.D. on 20 March, 1996. J. Ehrenkranz --- **Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JLW/K960195](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JLW/K960195) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com